[go: up one dir, main page]

WO2009114700A3 - Cell model of neurodegenerative disease and methods of use thereof for identifying inhibitors of mitochondrial fusion - Google Patents

Cell model of neurodegenerative disease and methods of use thereof for identifying inhibitors of mitochondrial fusion Download PDF

Info

Publication number
WO2009114700A3
WO2009114700A3 PCT/US2009/036973 US2009036973W WO2009114700A3 WO 2009114700 A3 WO2009114700 A3 WO 2009114700A3 US 2009036973 W US2009036973 W US 2009036973W WO 2009114700 A3 WO2009114700 A3 WO 2009114700A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
neurodegenerative disease
mitochondrial fusion
cell model
identifying inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/036973
Other languages
French (fr)
Other versions
WO2009114700A2 (en
Inventor
Asa Abeliovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of WO2009114700A2 publication Critical patent/WO2009114700A2/en
Publication of WO2009114700A3 publication Critical patent/WO2009114700A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The disclosure provides a method for identifying compounds that may be used in the treatment of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis. The disclosed methods provide a novel mammalian cell-based model of neurodegenerative diseases based on mitochondrial fusion and fission.
PCT/US2009/036973 2008-03-12 2009-03-12 Cell model of neurodegenerative disease and methods of use thereof for identifying inhibitors of mitochondrial fusion Ceased WO2009114700A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3583908P 2008-03-12 2008-03-12
US61/035,839 2008-03-12

Publications (2)

Publication Number Publication Date
WO2009114700A2 WO2009114700A2 (en) 2009-09-17
WO2009114700A3 true WO2009114700A3 (en) 2010-03-18

Family

ID=41065833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/036973 Ceased WO2009114700A2 (en) 2008-03-12 2009-03-12 Cell model of neurodegenerative disease and methods of use thereof for identifying inhibitors of mitochondrial fusion

Country Status (1)

Country Link
WO (1) WO2009114700A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009029656A1 (en) 2007-08-27 2009-03-05 Auxagen, Inc. METHODS FOR INHIBITING TGF-β
WO2010033507A1 (en) * 2008-09-16 2010-03-25 St. Louis University Method of enhancing tgf-beta signalling
WO2014059091A2 (en) * 2012-10-12 2014-04-17 Trustees Of Dartmouth College Methods for modulating mitochondrial function via inf2
WO2016111552A1 (en) 2015-01-06 2016-07-14 권영아 Luterion and separating and culturing methods for same
WO2018200323A1 (en) * 2017-04-23 2018-11-01 Washington University Small molecule regulators of mitochondrial fusion and methods of use thereof
EP3917509A4 (en) 2019-01-28 2022-11-09 Mitochondria Emotion, Inc. ACTIVATORS OF TRANS-4-HYDROXYCYCLOHEXYLPHENYLAMIDE DERIVATIVES OF MITOFUSIN AND METHODS OF USE THEREOF
AU2019427489B2 (en) 2019-01-28 2025-03-13 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168673A1 (en) * 1999-10-06 2002-11-14 Fuller Margaret T. Mitofusins, Fzo homologs and functional derivatives thereof
US20050038051A1 (en) * 2003-06-09 2005-02-17 Jodi Nunnari Novel molecules for regulating cell death
US20060084072A1 (en) * 2004-10-20 2006-04-20 University Of Washington Drug targets for the treatment of neurodegenerative disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168673A1 (en) * 1999-10-06 2002-11-14 Fuller Margaret T. Mitofusins, Fzo homologs and functional derivatives thereof
US20050038051A1 (en) * 2003-06-09 2005-02-17 Jodi Nunnari Novel molecules for regulating cell death
US20060084072A1 (en) * 2004-10-20 2006-04-20 University Of Washington Drug targets for the treatment of neurodegenerative disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NEWTON ET AL.: "Inhibition of dynamin completely blocks compensatory synaptic vesicle endocytosis.", PROC NATL ACAD SCI U S A., vol. 103, no. 47, 21 November 2006 (2006-11-21), pages 17955 - 17960 *
POOLE ET AL.: "The PINK1/Parkin pathway regulates mitochondrial morphology.", PROC NATL ACAD SCI U S A., vol. 105, no. 5, 5 February 2008 (2008-02-05), pages 1638 - 43 *

Also Published As

Publication number Publication date
WO2009114700A2 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
WO2009114700A3 (en) Cell model of neurodegenerative disease and methods of use thereof for identifying inhibitors of mitochondrial fusion
IL211540A (en) Optical method for the detection of alzheimer's disease
NZ602497A (en) Enterobacter sp. 638 and methods of use thereof
WO2014145104A3 (en) Apparatus, systems, and methods for analyzing characteristics of entities of interest
WO2008024376A3 (en) Method and system for teaching a foreign language
EP4415372A3 (en) Systems and methods for episode tracking in an interactive media environment
WO2008109847A3 (en) Methods of placing advertisments, interstitials and toolbars in a web browser
WO2011001135A3 (en) Diagnosis and treatment of alzheimer's disease
WO2007114901A3 (en) Method for diagnosing adhd and related behavioral disorders
WO2009088891A8 (en) Screening method for selected amino lipid-containing compositions
WO2008006422A3 (en) Use of ionic liquids or solutions of metal salts in ionic liquids as anti-static agents for plastics
WO2009098682A3 (en) Methods and compositions for treatment of mitochondrial disorders
BRPI0911482A2 (en) USE OF EPOTHYLONE D IN THE TREATMENT OF TAU-ASSOCIATED DISEASES INCLUDING ALZHEIMER DISEASES
WO2007140380A3 (en) Tagging reagents and methods for hydroxylated compounds
WO2010059241A3 (en) Treatment of amyotrophic lateral sclerosis
WO2009020601A3 (en) Atf4 inhibitors and their use for neural protection, repair, regeneration, and plasticity
GB0705416D0 (en) System and method for managing objects according to the common information model
WO2011029087A3 (en) Methods and systems for personal support and assistance
FR2967924B1 (en) NANOCHARGE OF A METAL OXIDE, PROCESS FOR THE SYNTHESIS AND USE THEREOF IN ANTI-ADHESIVE COATING BASED ON FLUOROCARBON RESIN
EP3049532A4 (en) Markers for amyotrophic lateral sclerosis (als) and presymptomatic alzheimer's disease (psad)
WO2009060829A1 (en) Advertisement presentation method, advertisement presentation system, and program
WO2010129665A3 (en) Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis
WO2010041252A3 (en) Use of a cinnamon bark extract for treating amyloid-associated diseases
AU2013292027A8 (en) Vehicle parking
WO2009040727A3 (en) Method of differentially diagnosing by spect different types of dementia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09719494

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09719494

Country of ref document: EP

Kind code of ref document: A2